6-K Filing

TEVA PHARMACEUTICAL INDUSTRIES LTD CIK: 818686 Q2 2017

Filing Information

Form Type	6-K
Accession Number	`0001193125-17-247510`
Period End Date	20170630
Filing Date	20170803
Fiscal Year	2017
Fiscal Period	Q2
XBRL Instance	teva-20170630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 76 Income Statement 92 Cash Flow Statement 72 Comprehensive Income 36

Balance Sheet 76 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$988.00M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.95B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$599.00M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.98B	USD	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$7.52B	USD	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$7.32B	USD	Point-in-time
Inventories	`InventoryNet`	$5.13B	USD	Point-in-time
Inventories	`InventoryNet`	$4.95B	USD	Point-in-time
Assets Held For Sale	`AssetsHeldForSale`	$21.00M	USD	Point-in-time
Assets Held For Sale	`AssetsHeldForSale`	$841.00M	USD	Point-in-time
Prepaid Expenses	`PrepaidExpenses`	$871.00M	USD	Point-in-time
Prepaid Expenses	`PrepaidExpenses`	$1.36B	USD	Point-in-time
Other Current Assets	`OtherCurrentAssets`	$652.00M	USD	Point-in-time
Other Current Assets	`OtherCurrentAssets`	$1.29B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$16.96B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$14.60B	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$1.25B	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$1.24B	USD	Point-in-time
Deferred Income Taxes	`NonCurrentDeferredIncomeTaxes`	$725.00M	USD	Point-in-time
Deferred Income Taxes	`NonCurrentDeferredIncomeTaxes`	$773.00M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$8.07B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$8.04B	USD	Point-in-time
Identifiable intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$21.49B	USD	Point-in-time
Identifiable intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$21.66B	USD	Point-in-time
Goodwill	`Goodwill`	$44.41B	USD	Point-in-time
Goodwill	`Goodwill`	$40.03B	USD	Point-in-time
Total assets	`Assets`	$92.89B	USD	Point-in-time
Total assets	`Assets`	$86.36B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$1.25B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$3.28B	USD	Point-in-time
Sales Reserves And Allowances	`SalesReservesAndAllowances`	$7.57B	USD	Point-in-time
Sales Reserves And Allowances	`SalesReservesAndAllowances`	$7.84B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$2.28B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$2.16B	USD	Point-in-time
Employee Related Obligations	`EmployeeRelatedObligations`	$712.00M	USD	Point-in-time
Employee Related Obligations	`EmployeeRelatedObligations`	$859.00M	USD	Point-in-time
Accrued Expenses	`AccruedExpenses`	$3.40B	USD	Point-in-time
Accrued Expenses	`AccruedExpenses`	$2.76B	USD	Point-in-time
Liabilities Held For Sale	`LiabilitiesOfAssetsHeldForSales`	-	USD	Point-in-time
Liabilities Held For Sale	`LiabilitiesOfAssetsHeldForSales`	$116.00M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$867.00M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$898.00M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$18.52B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$15.46B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$5.45B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$5.21B	USD	Point-in-time
Other taxes and long term liabilities	`OtherLiabilitiesNoncurrent`	$2.04B	USD	Point-in-time
Other taxes and long term liabilities	`OtherLiabilitiesNoncurrent`	$1.64B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$32.52B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$33.81B	USD	Point-in-time
Total long term liabilities	`LiabilitiesNoncurrent`	$41.29B	USD	Point-in-time
Total long term liabilities	`LiabilitiesNoncurrent`	$39.38B	USD	Point-in-time
Total liabilities	`Liabilities`	$57.90B	USD	Point-in-time
Total liabilities	`Liabilities`	$56.75B	USD	Point-in-time
Preferred Shares	`PreferredStockValue`	$3.62B	USD	Point-in-time
Preferred Shares	`PreferredStockValue`	$3.62B	USD	Point-in-time
Ordinary shares	`CommonStockValue`	$54.00M	USD	Point-in-time
Ordinary shares	`CommonStockValue`	$54.00M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$23.41B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$23.44B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$13.61B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$7.43B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-3.16B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.54B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.96B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.40B	USD	Point-in-time
Treasury shares	`TreasuryStockValue`	$4.15B	USD	Point-in-time
Treasury shares	`TreasuryStockValue`	$4.19B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$27.99B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$33.34B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.61B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.66B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$29.61B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$34.99B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$86.36B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$92.89B	USD	Point-in-time

Income Statement 92 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`SalesRevenueNet`	$9.85B	USD	2 Qtrs
Net revenues	`SalesRevenueNet`	$11.32B	USD	2 Qtrs
Net revenues	`SalesRevenueNet`	$5.04B	USD	1 Quarter
Net revenues	`SalesRevenueNet`	$5.69B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$2.87B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$4.18B	USD	2 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$5.68B	USD	2 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$2.16B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.82B	USD	1 Quarter
Gross profit	`GrossProfit`	$5.67B	USD	2 Qtrs
Gross profit	`GrossProfit`	$5.64B	USD	2 Qtrs
Gross profit	`GrossProfit`	$2.88B	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$486.00M	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$943.00M	USD	2 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$764.00M	USD	2 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$375.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$1.79B	USD	2 Qtrs
Selling and marketing expenses	`SellingAndMarketingExpense`	$960.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$1.93B	USD	2 Qtrs
Selling and marketing expenses	`SellingAndMarketingExpense`	$952.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$272.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$508.00M	USD	2 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$311.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$615.00M	USD	2 Qtrs
Impairments restructuring and others	`ImpairmentsRestructuringAndOthers`	$419.00M	USD	1 Quarter
Impairments restructuring and others	`ImpairmentsRestructuringAndOthers`	$712.00M	USD	1 Quarter
Impairments restructuring and others	`ImpairmentsRestructuringAndOthers`	$659.00M	USD	2 Qtrs
Impairments restructuring and others	`ImpairmentsRestructuringAndOthers`	$831.00M	USD	2 Qtrs
Legal Settlements And Loss Contingencies	`LegalSettlementsAndLossContingencies`	$141.00M	USD	2 Qtrs
Legal Settlements And Loss Contingencies	`LegalSettlementsAndLossContingencies`	$166.00M	USD	1 Quarter
Legal Settlements And Loss Contingencies	`LegalSettlementsAndLossContingencies`	$324.00M	USD	1 Quarter
Legal Settlements And Loss Contingencies	`LegalSettlementsAndLossContingencies`	$344.00M	USD	2 Qtrs
Goodwill Impairment Charge	`GoodwillImpairmentLoss`	$6.10B	USD	2 Qtrs
Goodwill Impairment Charge	`GoodwillImpairmentLoss`	-	USD	2 Qtrs
Goodwill Impairment Charge	`GoodwillImpairmentLoss`	$6.10B	USD	1 Quarter
Goodwill Impairment Charge	`GoodwillImpairmentLoss`	-	USD	1 Quarter
Operating (loss) income	`OperatingIncomeLoss`	$1.53B	USD	2 Qtrs
Operating (loss) income	`OperatingIncomeLoss`	$-4.84B	USD	2 Qtrs
Operating (loss) income	`OperatingIncomeLoss`	$361.00M	USD	1 Quarter
Operating (loss) income	`OperatingIncomeLoss`	$-5.74B	USD	1 Quarter
Financial expenses - net	`NonoperatingIncomeExpense`	$-238.00M	USD	1 Quarter
Financial expenses - net	`NonoperatingIncomeExpense`	$-445.00M	USD	2 Qtrs
Financial expenses - net	`NonoperatingIncomeExpense`	$-105.00M	USD	1 Quarter
Financial expenses - net	`NonoperatingIncomeExpense`	$-403.00M	USD	2 Qtrs
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$256.00M	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-5.98B	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-5.29B	USD	2 Qtrs
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.12B	USD	2 Qtrs
Income taxes (Benefit)	`IncomeTaxExpenseBenefit`	$29.00M	USD	1 Quarter
Income taxes (Benefit)	`IncomeTaxExpenseBenefit`	$32.00M	USD	2 Qtrs
Income taxes (Benefit)	`IncomeTaxExpenseBenefit`	$-22.00M	USD	1 Quarter
Income taxes (Benefit)	`IncomeTaxExpenseBenefit`	$257.00M	USD	2 Qtrs
Share in (profits) losses of associated companies net	`IncomeLossFromEquityMethodInvestments`	$-14.00M	USD	1 Quarter
Share in (profits) losses of associated companies net	`IncomeLossFromEquityMethodInvestments`	$-7.00M	USD	2 Qtrs
Share in (profits) losses of associated companies net	`IncomeLossFromEquityMethodInvestments`	$9.00M	USD	2 Qtrs
Share in (profits) losses of associated companies net	`IncomeLossFromEquityMethodInvestments`	$15.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-5.97B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-5.33B	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$242.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$875.00M	USD	2 Qtrs
Net loss attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-15.00M	USD	2 Qtrs
Net loss attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-4.00M	USD	2 Qtrs
Net loss attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-12.00M	USD	1 Quarter
Net loss attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-5.33B	USD	2 Qtrs
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-5.97B	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$254.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$890.00M	USD	2 Qtrs
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$65.00M	USD	1 Quarter
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$132.00M	USD	2 Qtrs
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$66.00M	USD	1 Quarter
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$130.00M	USD	2 Qtrs
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-6.04B	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$188.00M	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-5.46B	USD	2 Qtrs
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$758.00M	USD	2 Qtrs
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	2 Qtrs
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	914.00M	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	914.00M	shares	2 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	922.00M	shares	2 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	920.00M	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.02B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.02B	shares	2 Qtrs
Basic	`EarningsPerShareBasic`	$0.83	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$0.21	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-5.37	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$-5.94	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.20	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-5.94	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.82	USD	2 Qtrs
Diluted	`EarningsPerShareDiluted`	$-5.37	USD	2 Qtrs

Cash Flow Statement 72 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$-5.97B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-5.33B	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$242.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$875.00M	USD	2 Qtrs
Impairment Of Goodwill	`ImpairmentOfGoodwill`	$6.10B	USD	2 Qtrs
Impairment Of Goodwill	`ImpairmentOfGoodwill`	-	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$1.06B	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$615.00M	USD	2 Qtrs
Venezuela impairment of net monetary assets	`VenezuelaRemeasurementImpact`	$18.00M	USD	2 Qtrs
Venezuela impairment of net monetary assets	`VenezuelaRemeasurementImpact`	$246.00M	USD	2 Qtrs
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$-53.00M	USD	2 Qtrs
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$711.00M	USD	2 Qtrs
Deferred Income Taxes Net And Uncertain Tax Positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-202.00M	USD	2 Qtrs
Deferred Income Taxes Net And Uncertain Tax Positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-127.00M	USD	2 Qtrs
Research and development in process	`ResearchAndDevelopmentExpense`	-	USD	2 Qtrs
Research and development in process	`ResearchAndDevelopmentExpense`	$10.00M	USD	2 Qtrs
Impairment of long lived assets	`AssetImpairmentCharges`	$159.00M	USD	2 Qtrs
Impairment of long lived assets	`AssetImpairmentCharges`	$585.00M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$52.00M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$75.00M	USD	2 Qtrs
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$-126.00M	USD	2 Qtrs
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$-34.00M	USD	2 Qtrs
Net gain from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$65.00M	USD	2 Qtrs
Net gain from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$21.00M	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$2.34B	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.21B	USD	2 Qtrs
Acquisitions of subsidiaries, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	2 Qtrs
Acquisitions of subsidiaries, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$2.31B	USD	2 Qtrs
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$347.00M	USD	2 Qtrs
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$395.00M	USD	2 Qtrs
Purchases of investments and other assets	`PaymentToAquireMarketableSecuritiesAndOtherAssets`	$14.00M	USD	2 Qtrs
Purchases of investments and other assets	`PaymentToAquireMarketableSecuritiesAndOtherAssets`	$37.00M	USD	2 Qtrs
Proceeds from sales of business, investments and long-lived assets	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$1.49B	USD	2 Qtrs
Proceeds from sales of business, investments and long-lived assets	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$39.00M	USD	2 Qtrs
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$-15.00M	USD	2 Qtrs
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$286.00M	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-2.64B	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$790.00M	USD	2 Qtrs
Proceeds from issuance of ordinary shares, net of issuance costs	`ProceedsFromIssuanceOfCommonStock`	-	USD	2 Qtrs
Proceeds from issuance of ordinary shares, net of issuance costs	`ProceedsFromIssuanceOfCommonStock`	$329.00M	USD	2 Qtrs
Proceeds from issuance of mandatory convertible preferred shares, net of issuance costs	`ProceedsFromIssuanceOfPreferredStockAndPreferenceStock`	-	USD	2 Qtrs
Proceeds from issuance of mandatory convertible preferred shares, net of issuance costs	`ProceedsFromIssuanceOfPreferredStockAndPreferenceStock`	$329.00M	USD	2 Qtrs
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$-1.48B	USD	2 Qtrs
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$758.00M	USD	2 Qtrs
Dividends paid on ordinary shares	`PaymentsOfDividendsCommonStock`	$617.00M	USD	2 Qtrs
Dividends paid on ordinary shares	`PaymentsOfDividendsCommonStock`	$691.00M	USD	2 Qtrs
Dividends paid on preferred shares	`PaymentsOfDividendsPreferredStock`	$126.00M	USD	2 Qtrs
Dividends paid on preferred shares	`PaymentsOfDividendsPreferredStock`	$130.00M	USD	2 Qtrs
Dividends Paid To Non Controlling Interest	`PaymentsOfDividendsToNonControllingInterest`	$38.00M	USD	2 Qtrs
Dividends Paid To Non Controlling Interest	`PaymentsOfDividendsToNonControllingInterest`	-	USD	2 Qtrs
Proceeds from exercise of options by employees	`ProceedsFromStockOptionsExercised`	-	USD	2 Qtrs
Proceeds from exercise of options by employees	`ProceedsFromStockOptionsExercised`	$20.00M	USD	2 Qtrs
Proceeds from long-term loans and other long-term liabilities	`ProceedsFromLongTermLoansAndOtherLongTermLiabilities`	$521.00M	USD	2 Qtrs
Proceeds from long-term loans and other long-term liabilities	`ProceedsFromLongTermLoansAndOtherLongTermLiabilities`	$-2.00M	USD	2 Qtrs
Repayment of long-term loans And Other Long Term Liabilities	`RepaymentsOfLongTermDebt`	$43.00M	USD	2 Qtrs
Repayment of long-term loans And Other Long Term Liabilities	`RepaymentsOfLongTermDebt`	$583.00M	USD	2 Qtrs
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-102.00M	USD	2 Qtrs
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-21.00M	USD	2 Qtrs
Net cash used in (provided by) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.42B	USD	2 Qtrs
Net cash used in (provided by) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$546.00M	USD	2 Qtrs
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$-205.00M	USD	2 Qtrs
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$29.00M	USD	2 Qtrs
Net change in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$38.00M	USD	2 Qtrs
Net change in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-389.00M	USD	2 Qtrs
Balance of cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$988.00M	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$6.95B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$599.00M	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$6.98B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$988.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$6.95B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$599.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$6.98B	USD	Point-in-time

Comprehensive Income 36 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$-5.97B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-5.33B	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$242.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$875.00M	USD	2 Qtrs
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$406.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$872.00M	USD	2 Qtrs
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$346.00M	USD	2 Qtrs
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$91.00M	USD	1 Quarter
Unrealized gain (loss) on derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$521.00M	USD	2 Qtrs
Unrealized gain (loss) on derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$77.00M	USD	1 Quarter
Unrealized gain (loss) on derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$69.00M	USD	2 Qtrs
Unrealized gain (loss) on derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$185.00M	USD	1 Quarter
Unrealized gain (loss) on available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-17.00M	USD	1 Quarter
Unrealized gain (loss) on available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-265.00M	USD	2 Qtrs
Unrealized gain (loss) on available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$37.00M	USD	2 Qtrs
Unrealized gain (loss) on available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-66.00M	USD	1 Quarter
Unrealized gain (loss) on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-13.00M	USD	2 Qtrs
Unrealized gain (loss) on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	-	USD	1 Quarter
Unrealized gain (loss) on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	-	USD	2 Qtrs
Unrealized gain (loss) on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	-	USD	1 Quarter
Other Comprehensive Income (Loss)	`TotalOtherComprehensiveIncomeLoss`	$160.00M	USD	1 Quarter
Other Comprehensive Income (Loss)	`TotalOtherComprehensiveIncomeLoss`	$-312.00M	USD	1 Quarter
Other Comprehensive Income (Loss)	`TotalOtherComprehensiveIncomeLoss`	$-827.00M	USD	2 Qtrs
Other Comprehensive Income (Loss)	`TotalOtherComprehensiveIncomeLoss`	$440.00M	USD	2 Qtrs
Comprehensive Income (loss)	`ComprehensiveIncomeNetOfTax`	$-5.66B	USD	1 Quarter
Comprehensive Income (loss)	`ComprehensiveIncomeNetOfTax`	$-4.50B	USD	2 Qtrs
Comprehensive Income (loss)	`ComprehensiveIncomeNetOfTax`	$82.00M	USD	1 Quarter
Comprehensive Income (loss)	`ComprehensiveIncomeNetOfTax`	$435.00M	USD	2 Qtrs
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveLossAttributableToNonControllingInterests`	$136.00M	USD	1 Quarter
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveLossAttributableToNonControllingInterests`	$134.00M	USD	2 Qtrs
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveLossAttributableToNonControllingInterests`	$64.00M	USD	2 Qtrs
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveLossAttributableToNonControllingInterests`	$-2.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-54.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$301.00M	USD	2 Qtrs
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-5.66B	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-4.57B	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.